Brokerages expect Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report $876.61 million in sales for the current quarter, according to Zacks Investment Research. Nine analysts have issued estimates for Alexion Pharmaceuticals’ earnings, with estimates ranging from $847.72 million to $900.89 million. Alexion Pharmaceuticals posted sales of $831.00 million during the same quarter last year, which suggests a positive year-over-year growth rate of 5.5%. The firm is scheduled to announce its next quarterly earnings results on Thursday, February 15th.

According to Zacks, analysts expect that Alexion Pharmaceuticals will report full year sales of $876.61 million for the current year, with estimates ranging from $3.49 billion to $3.54 billion. For the next fiscal year, analysts forecast that the business will report sales of $4.07 billion per share, with estimates ranging from $3.91 billion to $4.28 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Alexion Pharmaceuticals.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, topping the consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The business had revenue of $859.00 million for the quarter, compared to analyst estimates of $864.34 million. During the same quarter in the previous year, the firm earned $1.23 EPS. The company’s quarterly revenue was up 7.5% compared to the same quarter last year.

A number of analysts recently issued reports on ALXN shares. Zacks Investment Research raised Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price objective for the company in a research report on Tuesday, October 31st. Oppenheimer Holdings, Inc. raised Alexion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $175.00 price objective for the company in a research report on Friday, July 28th. Royal Bank Of Canada started coverage on Alexion Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $161.00 price objective for the company. Morgan Stanley reissued an “overweight” rating and set a $153.00 price objective (up from $141.00) on shares of Alexion Pharmaceuticals in a research report on Friday, July 28th. Finally, TheStreet raised Alexion Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Friday, July 14th. Six research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $154.01.

WARNING: This article was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/11/05/zacks-brokerages-expect-alexion-pharmaceuticals-inc-alxn-will-post-quarterly-sales-of-876-61-million.html.

Alexion Pharmaceuticals (NASDAQ ALXN) opened at $117.95 on Friday. Alexion Pharmaceuticals has a fifty-two week low of $96.18 and a fifty-two week high of $149.34. The company has a current ratio of 2.96, a quick ratio of 2.51 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $26,351.21, a price-to-earnings ratio of 24.12, a PEG ratio of 1.29 and a beta of 1.22.

In related news, EVP Julie O’neill sold 4,375 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $145.44, for a total transaction of $636,300.00. Following the completion of the sale, the executive vice president now owns 26,092 shares in the company, valued at $3,794,820.48. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Ann M. Veneman sold 835 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total value of $121,751.35. Following the sale, the director now owns 5,480 shares of the company’s stock, valued at approximately $799,038.80. The disclosure for this sale can be found here. Over the last three months, insiders have sold 16,490 shares of company stock valued at $2,337,251. Corporate insiders own 4.35% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Commerzbank Aktiengesellschaft FI lifted its stake in Alexion Pharmaceuticals by 151.5% during the second quarter. Commerzbank Aktiengesellschaft FI now owns 132,698 shares of the biopharmaceutical company’s stock worth $16,145,000 after purchasing an additional 79,943 shares during the last quarter. HPM Partners LLC lifted its stake in Alexion Pharmaceuticals by 267.2% during the second quarter. HPM Partners LLC now owns 6,680 shares of the biopharmaceutical company’s stock worth $656,000 after purchasing an additional 4,861 shares during the last quarter. Principal Financial Group Inc. lifted its stake in Alexion Pharmaceuticals by 1.2% during the second quarter. Principal Financial Group Inc. now owns 335,525 shares of the biopharmaceutical company’s stock worth $40,823,000 after purchasing an additional 4,115 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in Alexion Pharmaceuticals by 4,509.0% during the third quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock worth $124,037,000 after purchasing an additional 864,967 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in Alexion Pharmaceuticals by 0.4% during the second quarter. Ameriprise Financial Inc. now owns 6,175,296 shares of the biopharmaceutical company’s stock worth $751,363,000 after purchasing an additional 25,724 shares during the last quarter. Hedge funds and other institutional investors own 94.55% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Get a free copy of the Zacks research report on Alexion Pharmaceuticals (ALXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.